Global Type 2 Diabetes Market 2016-2020

2型糖尿病治療薬の世界市場:インスリン、DPP-4阻害薬、GLP-1受容体作動薬、 SGLT-2阻害薬

◆タイトル:Global Type 2 Diabetes Market 2016-2020
◆商品コード:IRTNTR8779
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年3月23日
◆ページ数:122
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、2型糖尿病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、2型糖尿病治療薬の世界市場規模及び予測、薬剤種類別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

About Type 2 Diabetes

Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients’ blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types:
• Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas do not produce the required amount of insulin, leading to high blood glucose levels.
• Type 2 diabetes (non-insulin dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it, increasing the glucose levels in the body.
• Gestational diabetes: This condition occurs in pregnant women without any prior history of diabetes
Type 2 diabetes, also known as adult-onset diabetes, is a result of the body’s inability to produce enough insulin or insulin resistance or both. It is managed by providing symptomatic relief and improving the quality of life. Type 2 diabetes accounts for nearly 90%-95% of the total number of diabetes cases worldwide and is primarily diagnosed in the middle-aged and old age groups, i.e., between the ages of 30 and 75 years. However, it can occur even during childhood. The risks of type 2 diabetes include high blood pressure, advancing age, obesity, history of gestational diabetes, family history of diabetes, poor nutrition during pregnancy, physical inactivity, and impaired glucose tolerance.

Technavio’s analysts forecast the global type 2 diabetes drugs market to grow at a CAGR of 7.28% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global type 2 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat type 2 diabetes.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Type 2 Diabetes Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca plc
• Eli Lilly and Company
• Merck & Co. Inc.
• Novo Nordisk A/S
• Sanofi SA

[Other prominent vendors]
• Adocia
• Akros Pharma
• Amgen
• Astellas Pharma
• Biocon
• Boehringer Ingelheim
• Chipscreen Biosciences
• ConjuChem
• CymaBay Therapeutics
• Daiichi Sankyo
• DiaMedica
• Diasome Pharmaceuticals
• Dong-A ST
• Elcelyx Therapeutics
• Exsulin
• Generex
• Genfit
• Hanmi
• Hua Medicine
• InteKrin Therapeutics
• Ionis Pharmaceuticals
• Janssen Pharmaceuticals
• Japan Tobacco
• Kadmon
• KinDex Pharmaceuticals
• Kissei
• Kotobuki Pharmaceutical
• Lexicon Pharmaceuticals
• Ligand
• MannKind
• MedImmune
• Melior Pharmaceuticals
• Metabolic Solutions Development Company
• Mitsubishi Tanabe Pharma
• Novartis
• NGM Bio
• NuSirt Biopharma
• Oramed
• Peptron
• Pfizer
• PhaseBio
• Poxel
• Sanwa Kagaku Kenkyusho
• Sirona Biochem
• Takeda
• Theracos
• Theratechnologies
• Transition Therapeutics
• VeroScience
• vTv Therapeutics
• XBiotech

[Market driver]
• Rising prevalence of diabetes
• For a full, detailed list, view our report

[Market challenge]
• Low diagnosis rate
• For a full, detailed list, view our report

[Market trend]
• Increase in awareness of diabetes
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Disease overview
• Introduction
• Risk factors
• Diagnosis
• Management
• Epidemiology
• Economic burden

PART 06: Pipeline portfolio

PART 07: Market landscape
• Global diabetes drugs market
• Global type 2 diabetes drugs market
• Five forces analysis

PART 08: Market segmentation by drug class

PART 09: Insulin
• Product portfolio
• Global insulin market

PART 10: DPP-4 inhibitors
• Market overview
• Market size and forecast

PART 11: GLP-1 receptor agonists
• Market overview
• Market size and forecast

PART 12: SGLT-2 inhibitors
• Market overview
• Market size and forecast

PART 13: Geographical segmentation
• Global type 2 diabetes drugs market by geographical segmentation 2015-2020
• Type 2 diabetes drugs market in Americas
• Type 2 diabetes drugs market in EMEA
• Type 2 diabetes drugs market in APAC

PART 14: Market drivers
• Rising prevalence of diabetes
• Rise in obesity rates
• Growing older population
• Unmet medical needs
• Stringent regulatory guidelines for biosimilar drugs

PART 15: Impact of drivers

PART 16: Market challenges
• Low diagnosis rate
• Rising concerns in scientific community
• Gaps in national-level diabetes management plans
• Poor storage conditions and distribution policies for insulin
• Fierce market competition

PART 17: Impact of drivers and challenges

PART 18: Market trends
• Increase in awareness of diabetes
• Increase in academia-industry collaboration
• Rising price of diabetes drugs
• Increase in R&D

PART 19: Vendor landscape
• Competitive scenario
• Market analysis 2015
• Novo Nordisk
• Sanofi
• Merck
• Eli Lilly
• AstraZeneca
• Other prominent vendors

PART 20: Appendix0
• List of abbreviations

PART 21: Explore Technavio1

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for type 2 diabetes drugs
Exhibit 03: Line of therapy for type 2 diabetes
Exhibit 04: Pipeline portfolio: Global type 2 diabetes drugs market
Exhibit 05: Global diabetes drugs market by prevalence based on type of disease 2015
Exhibit 06: Top selling diabetes drugs based on sales 2014 ($ billions)
Exhibit 07: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
Exhibit 08: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 09: Market share analysis of vendors in global diabetes drugs market
Exhibit 10: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Segmentation of global type 2 diabetes drugs market by drug class
Exhibit 13: Segmentation of global type 2 diabetes drugs market by drug class 2015
Exhibit 14: Comparison of different classes of type 2 diabetes drugs
Exhibit 15: Global human insulin market 2015-2020 ($ billions)
Exhibit 16: Global insulin market revenues by type of diabetes 2015
Exhibit 17: Segmentation of global insulin market based by drug class 2015
Exhibit 18: Segmentation of global insulin market by geography 2015
Exhibit 19: DPP-4 inhibitor drugs approved in market
Exhibit 20: Global DPP-4 inhibitors drugs market for type 2 diabetes 2015-2020 ($ billions)
Exhibit 21: GLP-1 receptor agonists approved in market
Exhibit 22: Global GLP-1 receptor agonists drugs market for type 2 diabetes 2015-2020 ($ billions)
Exhibit 23: Segmentation of global GLP-1 receptor agonists drugs market for type 2 diabetes by geography 2015
Exhibit 24: Approved SGLT-2 inhibitor drugs
Exhibit 25: Global SGLT-2 inhibitors market for type 2 diabetes 2015-2020 ($ billions)
Exhibit 26: Segmentation of global type 2 diabetes drugs market by geography 2015
Exhibit 27: Global type 2 diabetes drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 28: Percentage share of global type 2 diabetes drugs market by geography 2015-2020
Exhibit 29: Type 2 diabetes drugs market in Americas 2015-2020 ($ billions)
Exhibit 30: Segmentation of type 2 diabetes drugs market in Americas by country 2015
Exhibit 31: Type 2 diabetes drugs market in US 2015-2020 ($ billions)
Exhibit 32: Type 2 diabetes drugs market in Brazil 2015-2020 ($ billions)
Exhibit 33: Type 2 diabetes drugs market in EMEA 2015-2020 ($ billions)
Exhibit 34: Type 2 diabetes drugs market in APAC 2015-2020 ($ billions)
Exhibit 35: Segmentation of type 2 diabetes drugs market in APAC by country 2015
Exhibit 36: Global type 2 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 37: Impact of drivers
Exhibit 38: Impact of drivers and challenges
Exhibit 39: YOY revenues from sales of top seven products in global type 2 diabetes drugs market 2012-2014 ($ billions)
Exhibit 40: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 41: Novo Nordisk: R&D expenditure 2015
Exhibit 42: Novo Nordisk: Key product offerings in global type 2 diabetes drugs market
Exhibit 43: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 44: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 45: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
Exhibit 46: Novo Nordisk: Revenues of NovoRapid/NovoLog by geography 2015
Exhibit 47: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 48: Novo Nordisk: Revenues of NovoMix/NovoLog Mix by geography 2015
Exhibit 49: Novo Nordisk: YOY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 50: Novo Nordisk: YoY revenue and growth rate of Victoza 2012-2015 ($ billions)
Exhibit 51: Novo Nordisk: YoY revenue and growth rate of Victoza in US 2013-2015 ($ billions)
Exhibit 52: Novo Nordisk: YoY revenue and growth rate of Victoza in Europe 2013-2015 ($ billions)
Exhibit 53: Novo Nordisk: YoY revenue and growth rate of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 54: Novo Nordisk: Key takeaways
Exhibit 55: Sanofi: Business segmentation by revenue 2015
Exhibit 56: Sanofi: Key product offerings in global type 2 diabetes drugs market
Exhibit 57: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 58: Sanofi: Geographical segmentation of Lantus by revenue 2015
Exhibit 59: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ millions)
Exhibit 60: Sanofi: Geographical segmentation of Amaryl by revenue 2015
Exhibit 61: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ millions)
Exhibit 62: Sanofi: Geographical segmentation of Toujeo by revenue 2015
Exhibit 63: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ millions)
Exhibit 64: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 65: Sanofi: Key takeaways
Exhibit 66: Merck: Business segmentation by revenue 2015
Exhibit 67: Merck: Diabetes segmentation by revenue 2015
Exhibit 68: Merck: Key product offerings in global type 2 diabetes drugs market
Exhibit 69: Merck: YoY revenue and growth rate of Janumet 2012-2015 ($ billions)
Exhibit 70: Merck: YoY revenue and growth rate of Januvia from 2012-2015 ($ billions)
Exhibit 71: Merck: Key takeaways0
Exhibit 72: Eli Lilly: Key product offerings in global type 2 diabetes drugs market1
Exhibit 73: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)1
Exhibit 74: Eli Lilly: YoY revenue and growth rate of Humalog in US 2013-2015 ($ billions)2
Exhibit 75: Eli Lilly: YoY revenue and growth rate of Humalog in ROW 2013-2015 ($ billions)2
Exhibit 76: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)3
Exhibit 77: Eli Lilly: YoY revenue and growth rate of Humulin in US 2013-2015 ($ millions)3
Exhibit 78: Eli Lilly: YoY revenue and growth rate of Humulin in ROW 2013-2015 ($ millions)3
Exhibit 79: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ millions)4
Exhibit 80: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)5
Exhibit 81: Eli Lilly: Trulicity geographical segmentation by revenue 20155
Exhibit 82: Eli Lilly: Key takeaways7
Exhibit 83: AstraZeneca: Key product offerings in global type 2 diabetes drugs market9
Exhibit 84: AstraZeneca: Farxiga/Forxiga geographical segmentation by revenues 20159
Exhibit 85: AstraZeneca: YoY revenues and growth rate of Byetta 2012-2015 ($ millions)0
Exhibit 86: AstraZeneca: YoY revenues and growth rate of Byetta in US ($ millions)0
Exhibit 87: AstraZeneca: YoY revenues and growth rate of Bydureon 2012-2015 ($ millions)1
Exhibit 88: AstraZeneca: YoY revenues and growth rate of Bydureon in US ($ millions)1
Exhibit 89: AstraZeneca: YoY revenues and growth rate of Onglyza 2012-2015 ($ millions)2
Exhibit 90: AstraZeneca: YoY revenues and growth rate of Onglyza/Kombiglyze XR/Komboglyze in US ($ millions)2
Exhibit 91: AstraZeneca: Key takeaways



【掲載企業】

AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, Sanofi SA, Adocia, Akros Pharma, Amgen, Astellas Pharma, Biocon, Boehringer Ingelheim, Chipscreen Biosciences, ConjuChem, CymaBay Therapeutics, Daiichi Sankyo, DiaMedica, Diasome Pharmaceuticals, Dong-A ST, Elcelyx Therapeutics, Exsulin, Generex, Genfit, Hanmi, Hua Medicine, InteKrin Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Japan Tobacco, Kadmon, KinDex Pharmaceuticals, Kissei, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Ligand, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Novartis, NGM Bio, NuSirt Biopharma, Oramed, Peptron, Pfizer, PhaseBio, Poxel, Sanwa Kagaku Kenkyusho, Sirona Biochem, Takeda, Theracos, Theratechnologies, Transition Therapeutics, VeroScience, vTv Therapeutics, XBiotech.

【資料のキーワード】

2型糖尿病、2型糖尿病治療薬、医薬品、インスリン、DPP-4阻害薬、GLP-1受容体作動薬、 SGLT-2阻害薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[2型糖尿病治療薬の世界市場:インスリン、DPP-4阻害薬、GLP-1受容体作動薬、 SGLT-2阻害薬] (Global Type 2 Diabetes Market 2016-2020 / IRTNTR8779)販売に関する免責事項
[2型糖尿病治療薬の世界市場:インスリン、DPP-4阻害薬、GLP-1受容体作動薬、 SGLT-2阻害薬] (Global Type 2 Diabetes Market 2016-2020 / IRTNTR8779)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆